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E11/podoplanin is critical in the early stages of osteoblast-to-osteocyte transitions
(osteocytogenesis), however, the upstream events which regulate E11 expression are
unknown. The aim of this study was to examine the effects of FGF-2 on E11-mediated
osteocytogenesis and to reveal the nature of the underlying signaling pathways
regulating this process. Exposure of MC3T3 osteoblast-like cells and murine primary
osteoblasts to FGF-2 (10 ng/ml) increased E11mRNAandprotein expression (p < 0.05)
after 4, 6, and 24 hr. FGF-2 induced changes in E11 expressionwere also accompanied
by significant (p < 0.01) increases inPhex andDmp1 (osteocytemarkers) expression and
decreases in Col1a1, Postn, Bglap, and Alpl (osteoblast markers) expression.
Immunofluorescent microscopy revealed that FGF-2 stimulated E11 expression,
facilitated the translocation of E11 toward the cell membrane, and subsequently
promoted the formation of osteocyte-like dendrites in MC3T3 and primary
osteoblasts. siRNA knock down of E11 expression achieved >70% reduction of basal
E11 mRNA expression (p < 0.05) and effectively abrogated FGF-2-related changes in
E11 expression and dendrite formation. FGF-2 strongly activated the ERK signaling
pathway inosteoblast-like cells but inhibitionof this pathwaydidnot block the ability of
FGF-2 to enhance E11 expression or to promote acquisition of the osteocyte
phenotype. The results of this study highlight a novel mechanism by which FGF-2 can
regulate osteoblast differentiation and osteocyte formation. Specifically, the data
suggests that FGF-2 promotes osteocytogenesis through increased E11 expression
and further studies will identify if this regulatory pathway is essential for bone
development and maintenance in health and disease.
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1 | INTRODUCTION
Osteocytes are derived from osteoblasts and are the most abundant
cells, residing inmineralized bone of the adult skeleton. It has long been
accepted that osteocytes are formed by the passive entrapment of
redundant osteoblasts by osteoid synthesized by their close neighbors
(Palumbo, Ferretti, & Marotti, 2004; Skerry, Bitensky, Chayen, &
Lanyon, 1989). The transition from the cuboidal-like osteoblastic
morphology to a dendritic shape characteristic of an osteocyte is,
however, a more active and tightly regulated process than originally
recognized (for reviews see Dallas & Bonewald, 2010; Franz-
Odendaal, Hall, & Witten, 2006).
The mechanisms which govern this osteoblast to osteocyte
transition (osteocytogenesis) are generally unknown but fundamen-
tal studies by Bonewald and coworkers identified E11/podoplanin, a
mucin-type transmembrane glycoprotein, as the earliest osteocyte
marker protein expressed during osteocytogenesis (Zhang et al.,
2006). Furthermore, E11 triggers actin cytoskeletal dynamics
(Staines et al., 2016), which are required for dendrite formation
and transient E11 knockdown blocks dendrite elongation (Zhang
et al., 2006). E11 glycoprotein is not unique to bone and is
ubiquitously expressed by many tissues in which it has a range of
regulatory functions including cell development, differentiation and
invasiveness, epithelial–mesenchymal transition, and oncogenesis
(Astarita, Acton, & Turley, 2012; Martín-Villar, Yurrita, Fernández-
Muñoz, Quintanilla, & Renart, 2009; Thiery, 2002; Wicki &
Christofori, 2007). Owing to its wide tissue expression, it is now
recognized by several names which include podoplanin in kidney
podocytes, T1α in alveolar type 1 epithelial cells, PA2.26 in skin
keratinocytes, gp38 in lymphoid organs, and E11 in lymphatic
endothelial cells, osteoblasts, and osteocytes (Breiteneder-Geleff
et al., 1997; Farr, Nelson, & Hosier, 1992; Ramirez et al., 2003;
Scholl, Gamallo, Vilaró, & Quintanilla, 1999; Wetterwald et al., 1996).
The intracellular signaling mechanisms by which E11 influences
dendrite formation involve the activation of the small GTPase, RhoA,
and its downstream effector kinase, ROCK (Martín-Villar et al.,
2006). ROCK phosphorylates ezrin/moesin/radixin (ERM) and
influences the actin cytoskeleton and subsequently cell shape
(Martín-Villar et al., 2006, 2014; Sprague, Wetterwald, Heinzman,
& Atkinson, 1996). Much less, however, is known about the
upstream regulatory events, specifically those that influence levels
of E11 expression during osteocytogenesis. Nonetheless, clues from
other model systems have indicated that fibroblast growth factor 2
(FGF-2) is able to change chondrocyte gene expression in vitro,
including that of E11 (Chong et al., 2013). FGF-2, one of the earliest
members identified in the FGF polypeptide family, signals through
FGF receptors that have intrinsic tyrosine kinase activity (Powers,
Mcleskey, & Wellstein, 2000). In addition to chondrocytes, FGF-2 is
expressed by osteoblasts and is stored in the extracellular matrix
where it regulates bone formation via influence on progenitor cell
lineage commitment and/or osteoblast differentiation (Hurley,
Marie, & Florkiewicz, 2002; Montero et al., 2000; Sabbieti et al.,
1999; Xiao et al., 2010). Indeed, mice deficient in Fgf2 have
decreased bone mass and altered trabecular architecture whereas
Fgf2 transgenic mice present with increased bone mineral density
and cortical and trabecular thickness, as well as a variety of skeletal
malformations including shortening and flattening of long bones
(Coffin et al., 1995; Montero et al., 2000; Xiao et al., 2009).
Cognizant of FGF-2 stimulation of E11 expression in cartilage
explants and osteoblast-like cells, we, therefore, hypothesized that
FGF-2 may influence bone remodeling via increased osteoblast E11
expression and concomitant osteocyte dendrite formation (Chong
et al., 2013; Gupta, Yoo, Hebert, Niger, & Stains, 2010). Hence, the
aims of this current studywere to examine the effects of FGF-2 on E11
expression in osteoblasts during osteocytogenesis and to explore
putative signaling pathways controlling this process.
2 | MATERIALS AND METHODS
2.1 | Animals
FGF-2-deficient mice (KO) were originally created by Tom Doetsch-
man and obtained from the Jackson Laboratory, and were backcrossed
onto a C57BL/6J wild-type (WT) background (Chong et al., 2013).
Animal experiments were performed after obtaining ethical and
statutory approval in accordance with local policy. Mice were
maintained in accordance with UK Home Office guidelines for the
care and use of laboratory animals.
2.2 | MC3T3 cell culture
Murine MC3T3-E1 (subclone 14), pre-osteoblast-like cells (American
Type Culture Collection [ATCC], Manassas, VA) were plated at 1 × 104
cells/cm2 in six-well plates and cultured in α-MEM medium
supplemented with 10% (v/v) FBS (Invitrogen, Paisley UK) and
50 µg/ml gentamicin (Invitrogen) at 37°C in a humidified atmosphere
with 5% CO2 and the medium was changed every 2–3 days. Cell
viability was assessed using a commercially available Alamar Blue kit
(Invitrogen) and cell cytotoxicity using an LDH assay according to the
manufacturer's instructions (Promega, Southampton, UK).
2.3 | Primary osteoblast isolation
Primary calvarial osteoblastswere obtained from3-day-oldWTmice by
serial enzyme digestion of dissected calvarial bones according to
published procedure (Orriss, Hajjawi, Huesa, Macrae, & Arnett, 2014;
Staines, Zhu, Farquharson, & Macrae, 2014). In brief, calvaria were
digested in 1mg/ml collagenase type II (Thermo Fisher Scientific,
Loughborough, UK) in Hanks’ balanced salt solution (HBSS) for 10min
and the supernatant discarded; then repeat digestion in 1mg/ml
collagenase type II in HBSS for 30min; 4mM EDTA for 10min and
finally 1mg/ml collagenase type II in HBSS for 30min. After discarding
the first digest, the cells were re-suspended in growth medium
consisting ofα-MEMsupplementedwith 10% (v/v) FBS andgentamycin
at 50 μg/ml. Osteoblasts were seeded at a density of 1 × 104 cells/cm2,
and incubated at 37°C/5%CO2 with media changes every 2–3 days.
2 | IKPEGBU ET AL.
2.4 | FGF-2 treatments
WhenMC3T3 cells and primary osteoblasts were confluent (day 0), the
culture media were replaced with α-MEM supplemented with 1% (v/v)
FBS, 50 µg/ml gentamicin and 0-50 ng/ml FGF-2 (PeproTech, London,
UK) in 0.1% bovine serum albumin (BSA). Each test condition was
completed in triplicate.
2.5 | Signaling inhibitors
MC3T3 cells were incubated with appropriate concentrations (specific
details in results) of the MEK1/2 inhibitor, U0126, the PI3K inhibitor,
LY294002 (InvivoGen, Toulouse, France), and the p38 inhibitor,
SB203580 (Cell Guidance Systems, Cambridge, UK). These inhibitors
have been reported to be selective for thesemolecules (Choi et al., 2008;
Hotokezakaetal., 2002;Macrae,Ahmed,Mushtaq,&Farquharson,2007).
Control cultures contained vehicle (0.1% dimethylsulfoxide, DMSO) only.
2.6 | RNA extraction and quantitative real-time PCR
(RT-qPCR)
Total RNA was extracted from MC3T3 cells and primary osteoblasts
using a Qiagen RNeasyMini kit (Qiagen, Manchester, UK) according to
the manufacturer's recommendations. The RNA samples were
reverse-transcribed into cDNA using Superscript II reverse transcrip-
tase (Invitrogen) according to the manufacturer's instructions.
RT-qPCR was carried out in a Stratagene Mx3000P cycler with each
reaction containing 50 ng template cDNA, 250 nM forward and
reverse primers (Supplementary Table S1), and PrecisionPlus Master-
mix (Primer Design, Chandler's Ford, UK). The cycle threshold (Ct)
values for the samples were normalized to that of Atp5b or Gapdh
(Supplementary Table S1) and the relative expression was calculated
using the 2ΔCt method (Livak & Schmittgen, 2001).
2.7 | Western blotting
Cells were scraped in RIPA lysis buffer containing protease inhibitors
(Roche, Germany), and protein concentrations were determined using
the Bio-RadproteinDCassay (Bio-Rad,HemelHempstead, UK). Protein
(8–15 µg)was separatedusinga10%Bis-Tris gel and then transferred to
a nitrocellulose membrane and probed with appropriate primary
antibody (Supplementary Table S2), and appropriate HRP-linked
secondary antibody (Supplementary Table S3). Immune complexes
were visualized by chemiluminescence using an ECL detection kit and
ECL film (GE Healthcare, Amersham, UK). HRP-conjugated anti β-actin
antibody (1:70,000, Sigma, Dorset UK) was used as a loading control.
Densitometry analysis of protein was performed using Image J (https://
imagej.nih.gov/ij/) (Baldari, Ubertini, Garufi, D'orazi, & Bossi, 2015).
2.8 | E11 immunofluorescence
MC3T3 cells were plated on cover slips at a density of 6.3 × 103 cells/
cm2 and following treatment with FGF-2, were fixed with 4%
paraformaldehyde (PFA) for 15min, washed in PBS and incubated in
blocking buffer (1× PBS, 5% normal donkey serum and 0.3% Triton
X-100) for 1 hr at room temperature (RT). E11 antibody (Supplemen-
tary Table S2) was added to each well (1:900 in 1× PBS, 0.3% Triton
X-100 and 1% BSA) overnight at 4°C. Control cells were incubated
with an equivalent concentration of goat IgG (Supplementary
Figure S1). Wells were subsequently incubated with AlexaFluor-
conjugated donkey anti-goat secondary antibodies (Supplementary
Table S3) in the dark for 2 hr at RT. Glass coverslipswere thenmounted
onto slides using ProLong Gold antifade reagent with DAPI (Thermo
Fisher Scientific) for nuclei staining (Dobie, Macrae, Huesa, Van't Hof,
& Ahmed, 2014). The slides were finally visualized using a Leica DMRB
fluorescence microscope and images were taken with a Leica DFC300
digital color camera (Leica, Milton Keynes, UK).
2.9 | Transfection of MC3T3 cells with E11 siRNA
E11 siRNA and scrambled siRNA stocks (Qiagen) were diluted to
10nM.MC3T3 cells were plated at 8 × 103 cells/cm2 andmaintained in
reduced serum medium. Cells were transfected as per manufacturer's
instructions with complexes of E11siRNA with HiPerFect (Qiagen),
while control cells were transfected with either complexes of
scrambled siRNA, with HiPerFect; or HiPerFect alone. After 24 hr
incubation at 37°C/5%CO2, FGF-2 (10 ng/ml) was added for a further
24 hr to the cells containing the siRNA/HiPerFect complexes or the
HiPerFect alone.
2.10 | Immunohistochemistry
The knee joints of 6-week-old male FGF-2 KO and WT mice (Chong
et al., 2013), were fixed in 4% PFA for 24 hr before decalcification in
10% ethylenediaminetetraacetic acid (EDTA) pH 7.4 for approxi-
mately 3 weeks at 4°C with regular changes. Tissues were
dehydrated and embedded in paraffin wax, using standard proce-
dures, after which they were sectioned at 6 µm. Sections were
dewaxed in xylene, rehydrated, and incubated at 37°C for 30 min in
1mg/ml trypsin for antigen demasking. Endogenous peroxidases
were blocked by treatment with 3% H2O2 in methanol. E11 and
sclerostin antibodies (Supplementary Table S2) were used with
appropriate IgG controls and secondary antibodies (Supplementary
Table S3). The Vectastain ABC universal kit (Vector Laboratories,
Peterborough, UK) was used according to the manufacturer's
instructions. The sections were dehydrated, counterstained with
haematoxylin and mounted in DePeX. Images were captured with
Nikon Eclipse Ni microscope (Nikon, UK), fitted with Zeiss Axiocam
105 color camera (Carl Zeiss). The number of positively stained E11
osteocytes within diaphyseal cortical bone were calculated as a
percentage of total osteocytes present.
2.11 | Phalloidin staining for cell culture
MC3T3 cells were seeded at 1 × 104 cells/cm2 and when sub-
confluent they were treated with 10 ng/ml FGF-2 or 0.1% BSA for
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control cultures. After 24 hr, the cells were fixed in 4% PFA,
rinsed in PBS and permeabilized in 0.1% (w/v) triton X-100 (Sigma)
in PBS for 10 mins, and then rinsed in PBS. The cells were
incubated in 200 μl of Alexa Fluor 488-conjugated phalloidin
(Thermo Fisher Scientific) (5 μM in PBS with 2% BSA) in the dark at
RT for 3 hr. The cells were imaged on a Zeiss Axiovert 25s inverted
microscope and digital imaging system (Carl Zeiss Microscopy, LLC,
Oberkochen, Germany).
2.12 | Phalloidin staining for histological sections
Femurs were decalcified as described above and then cryopro-
tected in 30% sucrose (w/v) at 4°C for 48 hr. The femora were cut
in the mediolateral plane in serial longitudinal 20 μm thick-sections
using a cryostat and thaw-mounted on gelatin-coated slides for
processing. Slides were dried at room temperature for 45 min,
washed in PBS twice for 5 min each, and incubated with 0.1%
Triton-X 100 (Sigma-Aldrich) for 30 min and then rinsed with PBS.
Slides were then incubated with Alexa Fluor 488-conjugated
phalloidin (1:20; Thermo Fisher Scientific) for 1 hr. Bone sections
were washed in PBS and mounted in VectaShield (Vector
Laboratories). Preparations were allowed to dry at room tempera-
ture for 12 hr. Sections were imaged on a Zeiss LSM 710 Laser
Scanning Confocal Microscope with 488 nm laser excitation and
detection settings from 493 to 634 nm. Z-stacks were produced
with optimal Nyquist overlap settings using a 63×/1.4na oil
immersion lens. Voxel sizes were 0.1 × 0.1 × 1.00 μm in x,y,z planes,
respectively. A comparable region of interest was analyzed for
osteocyte parameters in all samples located in the diaphyseal
cortical bone. Image stacks were imported into Bitplane Imaris 8.2.0
software and algorithms were created with Imaris FilamentTracer to
render and measure dendritic processes. Surface rendering was
used for osteocyte cell body measurements.
2.13 | Statistical analysis
Data are expressed as themean ± standard error of themean (S.E.M) of
at least three replicates per experiment. Statistical analysis was
performed by Student's t-test, one-way analysis of variance (ANOVA)
or a suitable non-parametric test. p < 0.05 was considered to be
significant and noted as *p values of <0.01 and <0.001were noted as **
and ***, respectively.
3 | RESULTS
3.1 | FGF-2 promotes osteoblast E11 gene and
protein expression
Treatment of MC3T3 cells with 10 ng/ml FGF-2 for 4, 6, and 24 hr
stimulated E11mRNA expression in comparison to control cultures, at
all time-points examined (p < 0.05, Figure 1a). We observed a
concomitant increase in E11 protein expression in these cells
(Figure 1b). Stimulation of E11 mRNA (p < 0.05, Figure 1c) and E11
protein (Figure 1d) expression by FGF-2 was similarly noted in primary
osteoblast cultures. The levels of FGF-2 induced E11mRNA and
protein were more prominent in the MC3T3 cells at the early time
points (4 and 6 hr), whereas in primary cells these increases peaked at
the later time points (24 hr) (Figure 1).
FIGURE 1 The effect of FGF-2 (10 ng/ml) on (a) E11 mRNA expression and (b) E11 protein expression in MC3T3 cells after 4, 6, and 24 hr
challenge, where (+) is FGF-2 treated cell, and (−) is untreated control. The effect of FGF-2 (10 ng/ml) on (c) E11 mRNA expression and (d)
E11 protein expression in primary osteoblast cells after 4, 6, and 24 hr challenge, where (+) is FGF-2 treated cell, and (−) is untreated control.
Results were normalized to the Atp5b housekeeping gene and β-actin for Western loading control. Data are presented as mean ± S.E.M for
n = 3; *p < 0.05; ***p < 0.001 compared to untreated cells
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3.2 | FGF-2 promotes osteoblast–osteocyte
differentiation
In light of the increased E11 expression by FGF-2, we next examined
the expression of known osteocyte and osteoblast marker genes to
determine whether exposure of osteoblast-like cells to FGF-2
promoted osteocytic differentiation. In MC3T3 cells, FGF-2 increased
the mRNA expression of the osteocyte marker Phex (phosphate
regulating endopeptidase homolog, X-linked) at 4 (p < 0.01), 6 (not
significant), and 24 (p < 0.001) hours (Figure 2a). Similarly, Dmp1
(dentin matrix protein 1) expression was significantly increased at both
6 and 24 hr in MC3T3 cells (p < 0.001; Figure 2b). In primary
osteoblasts, both Phex and Dmp1 mRNA expressions were also
increased by FGF-2 treatment, although the temporal changes were
slightly different to those observed in theMC3T3 cells. Specifically, the
stimulation of Phex expression by FGF-2was greater at late time points
whereas the up-regulation of Dmp1 was noted at earlier time points
when compared with MC3T3 cells (Figures 2c and 2d).
In contrast to the increased expression of osteocyte markers by
FGF-2, there was a consistent downward trend in the mRNA
expression of the osteoblast markers Col1a1 (collagen type 1), Bglap
(osteocalcin), Alpl (tissue non-specific alkaline phosphatase), and
Postn (periostin) in MC3T3 cells treated with exogenous FGF-2
(Figure 3a–d). This down-regulation of osteoblastic marker expression
was most consistently observed 24 hr after exposure to FGF-2,
although Alpl expression was also reduced at 4 (p < 0.001) and 6
(p < 0.01), as well as 24 (p < 0.001) hour time points (Figure 3c). A
similar down-regulation of Col1a1, Bglap, Alpl, and Postn expression
was also observed in FGF-2 treated primary osteoblast cells, whichwas
also most pronounced at longer (24 hr) times following FGF-2
challenge (Figure 3e–h). Together these data indicate that exposure
of MC3T3 as well as primary osteoblasts to exogenous FGF-2
promotes early expression of both E11 and osteocyte markers, with a
diminution in the expression levels of markers of the osteoblast
phenotype following only at later time points.
Assessment of cell viability in the FGF-2 treated MC3T3 cells by
the alamar blue assay revealed that after 24 hr of FGF-2 treatment
there was no significant differences between the control and FGF-2
treated cells (Figure 3i). We also observed a significant reduction in
LDH release in our FGF-2 treated cells (p < 0.05, Figure 3j) suggesting
that there is less cell death. Taken together, these data are consistent
with FGF-2 promoting E11 expression and osteoblast–osteocyte
differentiation in vitro.
3.3 | FGF-2 promotes E11 dependent osteocyte
dendrite formation
The differential regulation of osteoblast and osteocyte marker
genes, including E11, by FGF-2 strongly supports the tenet that
FGF-2 can induce osteocytogenesis. To examine this further, we
next investigated whether FGF-2 promotes the differentiation of
MC3T3 osteoblast-like cells into osteocytes with the adoption of
their characteristic dendritic appearance through alterations to the
intracellular cytoskeleton. We found that Phalloidin stained control
cells displayed a typical rounded morphology with little evidence of
dendrite formation (Figure 4a). In contrast, cells treated with FGF-2
for 24 hr displayed numerous delicate dendrites radiating from
individual cells and intertwining and connecting with dendrites from
neighbouring cells, in a manner characteristic of an osteocyte-like
phenotype (Figure 4b). To clarify E11 involvement in this FGF-2
FIGURE 2 The effect of FGF-2 (10 ng/ml) on the mRNA expression of (a) Phex and (b) Dmp1 in MC3T3 cells after 4, 6, and 24 hr challenge.
The effect of FGF-2 (10 ng/ml) on the mRNA expression of (c) Phex and (d) Dmp1 in primary osteoblast cells after 4, 6, and 24 hr challenge.
Results were normalized to the Atp5b housekeeping gene. Data are presented as mean ± S.E.M for n = 3; **p < 0.01; ***p < 0.001 compared to
untreated cells
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induced change to dendritic phenotype, MC3T3 cells were
challenged with FGF-2 for 24–72 hr and immunostained for E11
(Figure 4c). All FGF-2 treated MC3T3 cells exhibited modified
morphology with numerous E11 positive dendritic processes
radiating from the cell membrane (Figure 4c); these were only
rarely observed in control cells. Furthermore, the distribution of
intra-cellular E11 expression changed with both time in culture and
FGF-2 treatment. In control cells, it was mostly uniformly distributed
within the cytoplasm but after 72 hr in culture, cytoplasmic staining
appeared less strong and the predominant staining was associated
with focal accumulations at the cell membrane (Figure 4c). This
redistribution of E11 to the cell membrane was more obvious and
FIGURE 3 The effect of FGF-2 (10 ng/ml) on the mRNA expression of (a) Col1a1, (b) Bglap, (c) Alpl, and (d) Postn in MC3T3 cells after 4, 6,
and 24 hr challenge. The effect of FGF-2 (10 ng/ml) on the mRNA expression of (e) Col1a1, (f) Bglap, (g) Alpl, and (h) Postn in primary
osteoblast cells after 4, 6, and 24 hr challenge. Results were normalized to the Atp5b housekeeping gene. (i) Alamar blue assay for cell viability
and (j) LDH release assay in FGF-2 treated MC3T3 cells after 24 hr treatment. Data are presented as mean ± S.E.M for n = 3; *p < 0.05;
**p < 0.01; ***p < 0.001 compared to untreated cells
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more rapid in the FGF-2 treated cells, where it was achieved within
only 24 hr of treatment (Figure 4c). Similarly, FGF-2 promoted
dendrite formation and the re-distribution of E11 expression in
primary osteoblast cultures (Figure 4d). To determine if the
promotion of the osteocyte phenotype by FGF-2 was E11 mediated
we studied cells in which MC3T3 cells were transfected with E11
siRNA before being challenged with FGF-2 for 24 hr. E11 gene (77%
vs. mock control, 70% vs. scrambled control; p < 0.05; Figure 5a) and
protein (Figure 5b) expression were silenced successfully by E11
siRNA transfection. Immunofluorescence labeling for E11 and
phalloidin staining indicated that compared with mock or scrambled
control cell cultures, cells treated with FGF-2 developed less
dendrites after silencing of E11 expression (Figures 5c and 5d).
3.4 | FGF-2 cell signaling in MC3T3 cells is mediated
principally by phosphorylated ERK
FGF receptors (Fgfr) 1, 2, and 3, but not Fgfr4, were found to be
expressed by MC3T3 cells (data not shown). FGF-2 treatment had no
effect on Fgfr1 expression at all-time points studied (Figure 6a),
however, it reduced Fgfr2 (p < 0.01; Figure 6b) and Fgfr3 (p < 0.05;
Figure 6c) expression after 4 and 24 hr. Treatment of MC3T3 cells
with FGF-2 for 15 min revealed that of the pathways examined,
there was particularly marked ERK (p44/p42) activation (p < 0.001;
Figures 6d and 6e), while in comparison there was only slight
activation of both Akt (p < 0.01; Figures 6d and 6f) and p38 (p < 0.05;
Figures 6d and 6g), and no effect on JNK phosphorylation (Figures
FIGURE 4 The effect of FGF-2 (10 ng/ml) on MC3T3 osteoblast-like cell morphology. (a) Phalloidin staining for F-actin of control cultures,
and (b) FGF-2 treated cultures. Scale bar A & B = 150 μm). Immunofluorescence microscopy showing E11 expression and distribution in cells
treated with FGF-2 (10 ng/ml) for 24–72 hr in (c) MC3T3, and (d) primary osteoblasts. Note the arrows pointing at the dendrites. Images are
representative of three separate experiments. Scale bar c & d (i–vi) = 200 μm; c & d (vii–xii) = 150 μm)
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6d and 6h). Furthermore, the temporal expression of ERK activation
upon FGF-2 treatment revealed a sustained activation over a 48 hr
period (Figure 6i), which has been shown previously to be associated
with pathways leading to cell differentiation (Pellegrino & Stork,
2006). These data suggest that ERK activation, rather than
phosphorylation of alternative Akt, p38, or JNK mediated signaling
pathways is likely most influential in regulating E11 downstream of
FGF-2.
To further explore the likely role of MEK-ERK signaling in FGF-2
induced differentiation of osteoblast-like cells into osteocytes, we
next treated MC3T3 cells with the ERK inhibitor U0126 (25 μM) in
the presence or absence of FGF-2 (15 min). While ERK activation by
FGF-2 was blunted by U0126 (15 min) treatment (Figure 7a), the
prolonged treatment of cells with U0126 (24 hr) did not affect the
ability of FGF-2 to enhance E11 gene expression (Figures 7b and 7c).
Similarly, treatment of MC3T3 cells with p38 (SB203580) or PI3K
(LY294002) inhibitors did not affect the ability of FGF-2 to enhance
E11 expression (Figure 7d–g). Further investigations indicated that
Akt activation was increased in the presence of MEK inhibition by
U0126 and FGF-2 treatment (Figure 7h) and it is possible that this
FIGURE 5 The effect of E11siRNA transfection on FGF-2 (10 ng/ml) stimulation of E11 (a) mRNA. Results were normalized to the
Atp5b housekeeping gene. Data are presented as mean ± S.E.M for n = 3; *p < 0.05; ***p < 0.001 compared to untreated control cells;
#p < 0.05 refers to significant decrease of E11siRNA control when compared to the controls of scrambled and Mock treated cells (b)
The effect of FGF-2 (10 ng/ml) on E11 protein expression after E11 siRNA transfection, where (+) is FGF-2 treated cells, and (−) is
untreated cells. Results are normalized to β-actin for loading control. (c) Phalloidin staining for F-actin in E11 siRNA, mock and
scrambled cultures. Images are representative of three separate experiments. Scale bar = 100 μm. (d) Immunofluorescence staining for
E11 localization in E11 siRNA, mock and scrambled cultures. Images are representative of three separate experiments. Scale
bar = 150 μm
8 | IKPEGBU ET AL.
increased Akt signaling may be a compensatory change to allow
FGF-2 to promote E11 expression in the absence of full ERK
activation (Figures 7b and 7c). However, the combined inhibition of
MEK and PI3K signaling by the inhibitors U0126 and LY294002,
respectively, did not affect the ability of FGF-2 to enhance E11
protein expression (Figure 7i).
3.5 | Deletion of FGF-2 in vivo results in
dysfunctional osteocytogenesis
Finally, we used immunohistochemistry to examine whether FGF-2
KO mice exhibited altered skeletal E11 expression and distribution.
Unexpectedly, E11 staining in osteocytes situated within trabecular
FIGURE 6 The effect of FGF-2 (10 ng/ml) on the mRNA expression of (a) Fgfr1, (b) Fgfr2, and (c) Fgfr3 in MC3T3 cells after 4, 6, and 24 hr
challenge. Investigating the downstream signaling pathways involved in FGF-2 stimulation of E11 expression. (d) Western blotting analysis of
MC3T3 cells for phosphorylated and total p44/42 (ERK), Akt, p38, and JNK. Densitometry analysis of Western blotting revealed significant
upregulation of activated (e) p44/42, (f) Akt, and (g) p38 in treated MC3T3 cells with FGF-2 when compared to control cells. There was no
significant increase in (h) JNK expression in both cultures. (i) Western blotting analysis of MC3T3 cells for phosphorylated and total p44/42,
in MC3T3 cells treated with FGF-2 when compared to control cells showed an increase in phosphorylated p44/42 in the treated cells at all
time points. Results were normalized to the Atp5b housekeeping gene and β-actin for Western blotting loading control. Data are presented as
mean ± S.E.M for n = 4 and analyzed with student t-test. *p < 0.05; **p < 0.01; ***p < 0.001
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and cortical bone of FGF-2 KO mice appeared stronger than in
osteocytes from WT bones (Figure 8a–d). Quantification of the
number of E11 positive cells was, however, similar to those noted in
bones from WT mice (Figure 8e). No differences in sclerostin
expression or distribution in bones of FGF-2 KO mice in comparison
to those fromWT mice were observed (data not shown). Histological
analysis of osteocyte morphology in FGF-2 KO mice revealed
apparent increases in cell body volume (Figure 8a–d). To confirm and
extend these results, we performed phalloidin staining of osteocytes
in the cortical bone of FGF-2 KO and WT mice (Figures 9a and 9b).
We observed a significant increase in cell body volume (p < 0.05,
Figure 9c) in concordance with our histological observations. Despite
this, no differences in cell sphericity were observed (Figure 9d).
Similarly, the total number of dendrites (Figure 9e) and the dendrite
volume (Figure 9f) were unchanged between FGF-2 KO and WT
mice. We did, however, observe a significant decrease in average
dendrite volume in FGF-2 KO in comparison to WT mice (p < 0.01;
Figure 9g), suggestive of dysfunctional osteocytogenesis in FGF-2
KO mice.
4 | DISCUSSION
The transmembrane glycoprotein E11, has recently been recognized to
be an early driver of the osteoblast to osteocyte transition and the
acquisition of the dendritic phenotype (Gupta et al., 2010; Zhang et al.,
2006). Consistentwith previous data, herewe reveal that FGF-2 is able
to increase E11 expression and promotes osteocyte dendrite
formation, likely independent of intracellular signaling pathways that
may involve concomitant FGF-2 induced ERK activation.
Previous brief reports have shown that FGF-2 treatment of
osteoblast-like cells induces an increase in E11 expression and the
appearance of the osteocyte phenotype (Gupta et al., 2010;Miyagawa
et al., 2014). In this present study, we confirm and extend these
observations in both MC3T3 osteoblast-like cells and primary
osteoblasts. The significant upregulation of E11, Phex, and Dmp1
and down-regulation of Col1a1, Bglap, Alpl, and Postn in the FGF-2
treated cultures suggests that FGF-2 promotes the differentiation of
the osteoblast to the osteocyte stage. Concomitant with this,
fluorescence microscopy of cultured cells also disclosed altered E11
expression and localization within the differentiating osteoblast in
response to FGF-2. The presence of increased E11 in the cytoplasm
and perinuclear area suggests that FGF-2 not only stimulates E11
expression, but also facilitates the translocation of E11 toward the cell
membrane. Indeed, the ability of FGF-2 to alter subcellular protein
distribution is supported by a previous finding on the expression of
Twist and Spry4 proteins inmesenchymal stem cells (Lai, Krishnappa, &
Phinney, 2011). Here we observed E11 localization concentrated at
the base of the dendritic spikes of the osteocytes after 24–72 hr of
FGF-2 treatment. E11 immunofluorescence localization at osteocyte
dendritic projections has been reported inMLO-Y4 osteocyte-like cells
and primary osteocytes isolated from long bones (Stern et al., 2012). It
is, therefore, likely that this redistribution of E11 within the cell is
necessary for the transformation of the osteoblast from a cuboidal
shape to the osteocytic phenotype characterized by stellate-like
morphologywith long dendritic processes (Zhang et al., 2006).We also
reveal that these morphological changes do not occur because of
altered cell proliferation, nor do they precede cell death, therefore,
highlighting the role for FGF-2 in regulating E11 expression and
osteocyte differentiation in vitro.
FIGURE 7 (a) Western blot analysis of ERK signaling in the
presence (+) and absence (−) of U0126 (25 μm) incubation and
subsequent FGF-2 treatment. (b) Western blotting and (c) RT-qPCR
analysis of cells stimulated with FGF-2 for 24 hr, in the presence
or absence of U0126 (ERK inhibition). (d) Western blotting and
(e) RT-qPCR analysis of cells stimulated with FGF-2 for 24 hr, in the
presence or absence of LY294002 (Akt inhibition). (f) Western
blotting and (g) RT-qPCR analysis of cells stimulated with FGF-2 for
24 hr, in the presence or absence of SB203480 (p38 inhibition).
Effect of UO126 (25 μM) on Akt protein expression by (h) Western
blotting. (i) Effect of U0126 (25 μM) and LY294002 (10 μM), P-ERK,
and P-Akt inhibitors, respectively, on E11 protein expression.
Results were normalized to the Atp5b housekeeping gene and
β-actin for Western blotting loading control. Data are represented
as mean ± S.E.M for n = 3. Data are analyzed via one-way ANOVA;
p < 0.05 was considered to be significant. *p < 0.05
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The intracellular effects of FGF-2 are activated via binding to its cell
surface receptors, for example, FGFRs which have intrinsic receptor
tyrosine kinase activity. Signaling pathways downstream of FGF-2-
receptor binding are known to includeERK, p38, Akt, andPKC (Turner&
Grose, 2010). Of those examined in the present study, ERK showed the
most robust activation in response to FGF-2 in MC3T3 osteoblast-like
cells; although p38 and Akt phosphorylation was also significant.
Phosphorylation of ERK has been shown to mediate cell proliferation,
differentiation, andmatrixmineralization inhumanosteoblasts (Lai et al.,
2001; Marie, Miraoui, & Severe, 2012). The sustained activation of the
MEK-ERK pathway and phosphorylation of ERK over long time periods
suggests a central role for FGF-2 stimulation of cell differentiation
(Murphy, Mackeigan, & Blenis, 2003; Pellegrino & Stork, 2006). This is
supported by studies that report the importance of ERK signaling in
osteoblast initiation and commitment to the differentiation process (Lai
et al., 2001), and in osteocyte dendrite formation (Kyono, Avishai,
Ouyang, Landreth, &Murakami, 2012). Indeed, the conditional deletion
of ERK ablates the formation of osteocytes with characteristic dendritic
processes in vivo (Kyono et al., 2012).
Somewhat surprisingly, however, the MEK inhibitor, UO126 was
unable to block FGF-2's ability to promote E11 protein expression
despite a significant reduction in ERK activation. Similar results were
observed upon inhibition of PI3K/Akt and p38 signaling. These
results suggest that alternative pathways may exist by which FGF-2
is able to enhance E11 expression and osteocyte formation. Such
pathways may include the activation of p38 and Akt. Previous
reports have indicated that activation of p38 is involved in
osteoblast differentiation (Hu, Chan, Wang, & Li, 2003) whereas
Akt phosphorylation is associated with cell survival (Debiais et al.,
2004). The down regulation of Akt by FGF-2 has, however, also been
reported in human and mouse cells (Chaudhary & Hruska, 2001). In
our hands, however, the dual inhibition of Akt and ERK activation by
LY294002 and U0126, respectively, did not result in a block in E11
expression by FGF-2 and further work is required to unravel the
signaling pathways that mediate FGF-2 effect on the up-regulation
of E11 expression. The lack of JNK activation by FGF-2 in this study
is consistent with JNK phosphorylation (P-JNK) mediating late
osteoblast maturation (Matsuguchi et al., 2009).
Having shown that FGF-2 promotes E11 expression in MC3T3
osteoblast like-cells and murine primary osteoblasts, it was surprising
to note that E11 protein expression by early osteocytes appeared to be
increased in sections of bone from Fgf-2-deficient mice albeit no
FIGURE 8 Sections of (a and b) trabecular bone and (c and d) cortical bone osteocytes from Fgf-2 KO and WT mice immunostained for
E11. (a and b) Scale bar = 150 μm. (e) The number of E11 stained osteocytes was similar in cortical bone from Fgf-2 KO and WT mice. Images
are representative of three mice
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differences were noted in the number of E11 stained osteocytes. It is
recognized that heparin-like glycosaminoglycans can regulate the
signaling behavior of FGF-2 and, therefore, it is a possibility that in our
cell culture experiments FGF-2 is more available to the cells due to a
less mature extracellular matrix being formed (Padera, Venkataraman,
Berry, Godavarti, & Sasisekharan, 1999). Alternatively, the increased
E11 staining intensity in the osteocytes from Fgf-2-deficient mice is
maybe a compensatory response in an attempt to overcome the deficit
in FGF-2 related promotion of the osteoblast to osteocyte transition,
potentially through the upregulation of other members of the FGF
family. Similarly, it may simply be a consequence of the significantly
increased cell body volume observed in FGF-2 KO osteocytes. Indeed
FGF-2 has been reported to decrease chondrocyte hypertrophy in a
murine metatarsal organ culture model and as such, may play a similar
role in the formation of the osteocyte (Mancilla, De Luca, Uyeda,
Czerwiec, & Baron, 1998). Our phalloidin staining also revealed a
significant decrease in average dendrite length in FGF-2 KO mice
compared to WT mice; a similar phenotype to that observed in our
bone specific E11 conditional knockoutmice (Staines et al., 2017). This,
therefore, suggests that the absence of FGF-2 in vivo results in
dysfunctional osteocytogenesis.
In conclusion, these data taken together show that FGF-2
promotes the osteocyte phenotype and that this is mediated by
increased E11 expression which is redistributed within the differenti-
ating osteoblast. If further studies confirm this regulatory role for
FGF-2 in osteocyte formation, we will be in a better position to
understand the full repertoire of FGF-2 on bone cell function which
may provide insights into the etiology of skeletal disorders such as
osteoporosis and osteoarthritis.
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